Cellares argued that automation, closed manufacturing systems, and global production networks are the path to making cell therapy a broadly accessible medicine. Fabian Gerlinghaus outlined technical and operational steps—robotics for aseptic handling, standardized closed‑loop manufacturing modules, and synchronized supply chains—to reduce cost‑per‑dose and increase throughput beyond niche commercial centers. The company positioned its approach as a response to current bottlenecks in autologous and allogeneic cell manufacturing, emphasizing that consistent, automated processes will be required to meet demand as indications expand and regulators push for reproducible quality control across sites.